uploads/2018/10/Graph-8-3-1.png

BSX’s Endoscopy Business: Revenue Trends

By

Updated

Performance in 2018 YTD

Endoscopy is one of the two operating segments in Boston Scientific’s (BSX) MedSurg reporting segment. In the first nine months of 2018, Boston Scientific’s Endoscopy business reported revenues of $1.3 billion, which is a YoY (year-over-year) increase of 10.32%.

Of these revenues, BSX earned $724.0 million from the US market, which is a YoY rise of 9.9% on a reported basis and 9.8% on an operational basis. International markets contributed the remaining $580.0 million in revenues, which is a YoY rise of 11.3% on a reported basis and 8.3% growth on an operational basis.

Article continues below advertisement

Performance in the third quarter

In the third quarter, BSX’s Endoscopy business reported revenues of $443.0 million, which is a YoY rise of 10.1% on a reported basis, 11.6% growth on an operational basis, and 11.6% organic growth. Of these revenues, the company earned $247.0 million from the US market, which is a YoY rise of 12.5%.

The company’s international markets contributed the remaining $196.0 million in revenues, which is a YoY rise of 7.4% on a reported basis and 10.9% growth on an operational basis.

According to the company’s third-quarter earnings investor presentation, this performance was driven by robust demand for Boston Scientific’s core Endoscopy products. Its performance was also driven by the infection prevention and pathology products added to the company’s portfolio through the acquisition of EndoChoice.

According to the third-quarter earnings investor presentation, newly launched products such as Orise Gel, Axios Transluminal Stent, and SpyGlass DS II Visualization System are expected to strengthen Boston Scientific’s endoscopy portfolio in fiscal 2019.

Boston Scientific is also rapidly advancing the development of various single-use scopes such as the Exalt-D duodenoscope, upper gastrointestinal scope, bronchoscope, and surgical scope.

On March 5, Boston Scientific announced the acquisition of EMcision, allowing the company to add a novel radiofrequency ablation device used to treat pancreaticobiliary cancers.

Advertisement

More From Market Realist